Independent GLP-1 journalism
Practical
US pricing, coverage fights, Medicare and cash programs.
29 pieces
SELECT enrolled seventeen thousand people with heart disease and no diabetes, and found a twenty percent reduction in cardiovascular events. The label change that followed did more for access than any argument about obesity ever has.
The cardiovascular benefit holds in older adults. So does the muscle loss, onto a body that was already losing muscle, in a person for whom a fall is a different event than it was at forty.
Surgery still produces more weight loss than any injection, and it is now being declined by people who would have accepted it three years ago. Both of those facts deserve more scrutiny than they usually get.
Most of what determines how your first year goes is decided in the fortnight before the first injection, by questions nobody thinks to ask until much later.
Berberine, apple cider vinegar, fibre blends and anything sold as a GLP-1 activator. Some of them do something measurable. None of them does the thing they are being bought for.
There are more approved weight-loss drugs than most people realise, and they are not close to each other in effect. Knowing the order matters, because plenty of plans will only cover the bottom of it.
Clinical eligibility is a short, public, unambiguous rule. Whether anyone will pay for it is a completely separate question, and conflating the two is why so many people believe they were turned down for being too healthy.
Creatine, psyllium and a multivitamin are commodities. Put a GLP-1 label on the tub and the price roughly triples, which is a marketing achievement rather than a pharmacological one.
An entire industry has assembled around the answer being yes. The defensible answer is that two products help most people, two help some, and the rest exist because you are a motivated buyer with a new prescription.
Almost every avoidable failure I see in the first year of treatment traces back to the same thing: nobody wrote anything down. Here is what is worth recording, why it matters more on these drugs than on anything else I prescribe, and the tool I have settled on.
For three years the comparison between semaglutide and tirzepatide was made by holding two separate trials side by side, which is not a comparison. A direct trial changed that — and the result matters less to your decision than you would think.
Ozempic and Wegovy contain the same drug. Which one lands in your hand is decided almost entirely by your insurance plan and your diagnosis code — not by your body.
A negotiated price, a direct-purchase channel and a Medicare pilot. It is the largest change to GLP-1 access in America since the drugs arrived — and the fine print decides whether any of it reaches you.
Fatty liver disease is common, largely undiagnosed, and now has a GLP-1 approved to treat it. For patients whose plans exclude weight-loss drugs, that is not a footnote — it is a different prescription.
Compounded semaglutide filled a real gap during a genuine shortage. The regulatory basis for that gap has narrowed — and the market has not gone anywhere. Here is how to reason about it.
A trial stopped early for efficacy, a label expanded, and a benefit that has almost nothing to do with weight. If you have type 2 diabetes and chronic kidney disease, this is the most important thing in your file.
When Zepbound was approved for obstructive sleep apnea, it stopped being a weight-loss drug in the eyes of a large part of the American payment system. That distinction is worth thousands of dollars a year to some people.
Both makers now sell straight to patients, below list, outside the insurance machinery. For the uninsured it is the biggest practical change in years — and it quietly reprices the entire gray market.
An effective GLP-1 in tablet form is not mainly a convenience story. It is a manufacturing story — and manufacturing is what has rationed these drugs since the day they arrived.
An oral GLP-1 for obesity removes the needle, the fridge and a good deal of the friction. It also comes with rules about how you take it that people underestimate badly.
Patent expiry in several countries has produced generic semaglutide at a fraction of the American price. The US patent runs years longer, which is already driving people toward routes that carry real risk.
Having your GLP-1 covered today tells you very little about January. Employers are narrowing benefits, states are dropping them, and the people affected usually find out at the pharmacy counter.
Taking a fraction of the standard dose is now common enough to have its own vocabulary and its own influencers. Some of the reasoning is sound. Almost none of it has been tested.
Most denials are not clinical judgments. They are documentation failures, and documentation failures are the kind you can fix — if you know what the reviewer on the other end is actually reading.
A single clause written in 2003, before anyone had a weight-loss drug worth arguing about, now shapes the entire American market. It is the most expensive sentence in obesity medicine.
List price, negotiated price, coupon price, cash price, compounded price. Five numbers, none of which is the price, and only one of which you will ever be quoted.
A monthly fee, a fifteen-question form, and a prescription in under ten minutes. Some of these services provide genuinely good care. Distinguishing them from the ones selling access is harder than it should be.
Every article about these drugs ends at goal weight. That is roughly the midpoint. The second year is quieter, stranger, and the part where most of the decisions that matter actually get made.
Regain after stopping is not a failure of willpower or a scandal about the drugs. It is what happens when you withdraw treatment for a chronic condition — and it is entirely predictable, which is why it should be discussed in month one, not month twenty.
Also in Practical
On The Jab
The
GLP‑1
Handbook
Dr. Nick Robertson
MD
The book · 14 chapters
Everything I tell my own patients before their first injection. 214 pages of what actually matters in the first year — dosing, side effects, food, muscle, cost, and the part nobody prepares you for: maintenance.
Priced at four dollars because it should be affordable to everyone taking these drugs — not because it's worth four dollars. No upsell, no course, no supplement line.